These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23651163)

  • 1. Methotrexate: should we start using it in clinical practice?
    Miheller P; Kiss LS; Mandel M; Lakatos PL
    Curr Drug Targets; 2013 Nov; 14(12):1480-9. PubMed ID: 23651163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose methotrexate in inflammatory bowel disease: current status and future directions.
    Schröder O; Stein J
    Am J Gastroenterol; 2003 Mar; 98(3):530-7. PubMed ID: 12650783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of methotrexate in inflammatory bowel disease.
    Gabbani T; Deiana S; Lunardi S; Manetti N; Annese V
    Expert Opin Drug Saf; 2016 Oct; 15(10):1427-37. PubMed ID: 27462711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of methotrexate in an inflammatory bowel diseases based on the review of the current literature].
    Klimczak K; Łykowska-Szuber L; Krela-Kaźmierczak I; Eder P; Szymczak A; Stawczyk-Eder K; Linke K
    Wiad Lek; 2016; 69(2 Pt 2):262-6. PubMed ID: 27487545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease].
    Gomollón F; Rubio S; Charro M; García-López S; Muñoz F; Gisbert JP; Domènech E;
    Gastroenterol Hepatol; 2015 Jan; 38(1):24-30. PubMed ID: 25454602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with the use of low-dose methotrexate for inflammatory bowel disease.
    Soon SY; Ansari A; Yaneza M; Raoof S; Hirst J; Sanderson JD
    Eur J Gastroenterol Hepatol; 2004 Sep; 16(9):921-6. PubMed ID: 15316419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of methotrexate in patients with inflammatory bowel diseases.
    Preiss JC; Zeitz M
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S151-5. PubMed ID: 21044450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
    Bischoff A
    MMW Fortschr Med; 2010 Jan; 152(1-2):20. PubMed ID: 20302159
    [No Abstract]   [Full Text] [Related]  

  • 11. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunosuppression in inflammatory bowel disease: When, how and how long?].
    Gross V
    Dtsch Med Wochenschr; 2012 Sep; 137(37):1803-5. PubMed ID: 22956222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulse cyclophosphamide therapy for inflammatory bowel disease.
    Barta Z; Tóth L; Zeher M
    World J Gastroenterol; 2006 Feb; 12(8):1278-80. PubMed ID: 16534885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
    Schröder O; Blumenstein I; Stein J
    Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of chronic inflammatory bowel disease based on evidence and according to stage: top down].
    Mudter J; Neurath MF
    Dtsch Med Wochenschr; 2013 Sep; 138(36):1779. PubMed ID: 24002879
    [No Abstract]   [Full Text] [Related]  

  • 16. [Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD].
    Reinisch W; Dejaco C; Knoflach P; Petritsch W; Vogelsang H; Tilg H
    Z Gastroenterol; 2004 Sep; 42(9):1033-45; discussion 1046-7. PubMed ID: 15455280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate for maintenance of remission in Crohn's disease.
    Patel V; Macdonald JK; McDonald JW; Chande N
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006884. PubMed ID: 19821390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis.
    Khan KJ; Dubinsky MC; Ford AC; Ullman TA; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):630-42. PubMed ID: 21407186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease.
    Vandell AG; DiPiro JT
    Pharmacotherapy; 2002 May; 22(5):613-20. PubMed ID: 12013360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.